Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Geriatric Ward, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Psychooncology. 2017 Dec;26(12):2238-2244. doi: 10.1002/pon.4453. Epub 2017 May 31.
To evaluate the association between androgen deprivation therapy (ADT) and depression and to identify the risk factors for depressive symptoms among prostate cancer (PCa) patients who received ADT.
We conducted a prospective, longitudinal, controlled study and assessed 3 groups of older patients: the ADT group (men who were presented with maximum androgen block); the radical prostatectomy (RP) group (PCa control group: men who underwent RP without ADT); and the benign prostatic hyperplasia (BPH) group (men who had BPH). All patients completed the demographic questionnaire at baseline and the Zung Self-Rating Depression Scale (SDS) at pretreatment baseline, 1 month, 6 months, 9 months, 12 months and 15 months.
A total of 146 patients completed the study during the 15-month follow-up. The Self-Rating Depression Scale scores of the 3 groups showed significant differences at 1 month (P < .001), 6 months (P = .009), 9 months (P < .001), 12 months (P < .001), and 15 months (P < .001). At 9 months, 12% of the men in the ADT group, 4.3% in the RP group, and 2% in the BPH group showed depressive symptoms, and there were no significant differences (P = .095). However, there were significant differences among the 3 groups relative to the incidence of depressive symptoms at 12 and 15 months (P < .001, P = .007, respectively). The analysis of the ADT subgroup indicated that alcohol consumption (odds ratio = 6.868; P = .046; 95% CI, 1.038-45.443) and smoking (odds ratio = 13.661; P = 0.013; 95% CI, 1.722-108.386) increased the risk for developing depressive symptoms.
Androgen deprivation therapy use does significantly increase the depressive scores and enhance the incidence of depression among PCa patients who received ADT. Smoking and alcohol consumption are associated with depressive symptoms among PCa patients receiving ADT.
评估去势治疗(ADT)与抑郁之间的关联,并确定接受 ADT 的前列腺癌(PCa)患者出现抑郁症状的风险因素。
我们进行了一项前瞻性、纵向、对照研究,评估了 3 组老年患者:ADT 组(接受最大雄激素阻断治疗的男性);根治性前列腺切除术(RP)组(PCa 对照组:未接受 ADT 的接受 RP 的男性);良性前列腺增生(BPH)组(患有 BPH 的男性)。所有患者在基线时均完成了人口统计学问卷,并在治疗前基线、1 个月、6 个月、9 个月、12 个月和 15 个月时完成了 Zung 自评抑郁量表(SDS)。
在 15 个月的随访期间,共有 146 名患者完成了研究。3 组的 SDS 评分在 1 个月(P<0.001)、6 个月(P=0.009)、9 个月(P<0.001)、12 个月(P<0.001)和 15 个月(P<0.001)时均有显著差异。在 9 个月和 12 个月时,ADT 组有 12%的男性、RP 组有 4.3%的男性和 BPH 组有 2%的男性出现抑郁症状,但无显著差异(P=0.095)。然而,3 组在 12 个月和 15 个月时抑郁症状的发生率存在显著差异(P<0.001,P=0.007)。ADT 亚组分析表明,饮酒(比值比=6.868;P=0.046;95%CI,1.038-45.443)和吸烟(比值比=13.661;P=0.013;95%CI,1.722-108.386)增加了出现抑郁症状的风险。
去势治疗的使用确实会显著增加接受 ADT 的 PCa 患者的抑郁评分并增加其抑郁发生率。吸烟和饮酒与接受 ADT 的 PCa 患者的抑郁症状相关。